[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-433603-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-433603-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","is-c3c-structure-useful-as-biomarkers-for-epithelial-ovarian-cancer-editorial","Is C3c structure useful as biomarkers for epithelial ovarian cancer? - Editorial","","Editorial discussing whether complement C3c structures can serve as biomarkers for epithelial ovarian cancer (EOC). Highlights the clinical challenge of early EOC detection due to lack of cost-effective screening and symptom-free presentation. Reviews findings from Dr. Chen and colleagues reporting increased plasma C3c levels and correlation with EOC occurrence and progression, while questioning robustness. Raises concerns about statistical significance, outliers, stage-specific differences, and scatter distributions that may undermine claims.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/is-c3c-structure-useful-as-biomarkers-for-epithelial-ovarian-cancer-editorial/433603/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/is-c3c-structure-useful-as-biomarkers-for-epithelial-ovarian-cancer-editorial/433603.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early diagnosis of epithelial ovarian cancer still difficult?","Question",{"text":63,"@type":64},"EOC remains challenging because there is no cost-effective screening approach, symptoms are often absent in early disease, and the confirmed diagnosis is typically made at an advanced stage.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What biomarker claim is being evaluated regarding C3c?",{"text":68,"@type":64},"The discussion evaluates whether canonical complement C3 derivatives (C3c) measured in plasma correlate strongly with both the occurrence and progression of EOC.",{"name":70,"@type":61,"acceptedAnswer":71},"What concerns are raised about the reliability of the C3c biomarker conclusion?",{"text":72,"@type":64},"The editorial questions whether the reported significance is supported after considering that many values are below 1.0 μg/mL, potential confounding from outliers, lack of clear stage I vs stage II differences, and wide scatter across EOC groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},433603,1790834876,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":55,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","J Chin MedAssoc  \nEditorial  \nIs C3c structure useful as biomarkers for epithelial ovarian cancer?  \nPeng-Hui Wanga,b,c,*, Wei-Ting Chaoa,b, Tsung-Cheng Kuod,*  \naDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cFemale Cancer Foundation, Taipei, Taiwan, ROC; dDepartment of Obstetrics and Gynecology, Kuo General Hospital, Tainan, Taiwan, ROC  \nUnlike to high possibility to eradicate cervical cancer by avery highly effective strategy, including human papilloma virus (HPV) vaccination and cytology-based plus HPV-based screening (combo test),1–3 epithelial ovarian cancer (EOC) is still a big challenge due to the absence of cost-effective screening method and uncertainty of main etiology. Additionally, indulgent clinical course and symptom-free clinical presentation make an early diagnosis nearly impossible, and the advanced stage is a result when the confirmed diagnosis is made.4 Moreover, the incidence of EOC is continuously increasing.5 All result in a high mortality rate of EOC patients.6 In fact, EOC is the most lethal female genital tract cancer and is also associated with a heavy socioeconomic burden in the world.4–6 Although better understandings of pathophysiology of cancers plus far advance in modern medicine may help to combat many types of cancers effectively, there is no doubt that cancer stage is still the most powerful and independent risk factor for both progression-free survival (PFS) and overall survival (OS) .7–9 The limitation still apparently exists, even though therapy based on biomarkerstargeted therapy, genomic investigation, and following multimodality approach has provided cancer patient with a promising and exciting therapeutic efficacy.7,8,10–13 These aforementioned new landscapes of treatment of choice not only improve both PFS and OS rates but also apparently maintain the quality of life (QoL) in these cancer survivors after treatment.7–13 All strongly hint us the importance of an early diagnosis and following prompt adequate and effective therapy.1–3 Therefore, many bench and bed researchers are eagerly searching for more biomarkers to make the dream come true. One of the articles published in the Journal of Chinese Medical Association (JCMA) is a typical example which addressed this topic. Dr. Chen et al14 attempted to offer a better tool to fill in the gap. They found redefined complement C3c structures have significant increase  \n*Address correspondence. Dr. Peng-Hui Wang, Department of Obstetricsand Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, [ROC. E-mail address: phwang@vghtpe.gov.tw](ROC. E-mail address: phwang@vghtpe.gov.tw); [pongpongwang@gmail.com](pongpongwang@gmail.com) (P.-H. Wang); Dr. Tsung-Cheng Kuo, Department of Obstetrics and Gynecology, Kuo General Hospital, 22, Section 2, Minsheng Road, Tainan 700, Taiwan. E-mail address: [tckuo@kgh.com.tw](tckuo@kgh.com.tw) (T.-C. Kuo).  \nConflicts of interest: Dr. Peng-Hui Wang, an editorial board member at the Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other authors declare no conflicts of interest related to the subject matter or materials discussed in this article.  \nJournal of Chinese Medical Association. (2025): 88: 493-494.  \nReceived May 27, 2025; accepted May 28, 2025. doi: 10. 1097/JCMA.0000000000001253  \nCopyright © 2025, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc-nd/4.0/](by-nc-nd/4.0/))  \nin the plasma of EOC patients. This article is interesting and worthy of further discussion.  \nDr. Chen et al14 found canonical complement C3 derivatives as C3c having a strong correlation between incre","cbCaifanSFWOW9cN","https://ap.wps.com/l/cbCaifanSFWOW9cN","pdf",274747,"English","# Editorial\n## Clinical background and need for biomarkers\n## Discussion of reported C3c findings\n## Methodological/statistical concerns\n## Stage differentiation and interpretation","[{\"question\":\"Why is early diagnosis of epithelial ovarian cancer still difficult?\",\"answer\":\"EOC remains challenging because there is no cost-effective screening approach, symptoms are often absent in early disease, and the confirmed diagnosis is typically made at an advanced stage.\"},{\"question\":\"What biomarker claim is being evaluated regarding C3c?\",\"answer\":\"The discussion evaluates whether canonical complement C3 derivatives (C3c) measured in plasma correlate strongly with both the occurrence and progression of EOC.\"},{\"question\":\"What concerns are raised about the reliability of the C3c biomarker conclusion?\",\"answer\":\"The editorial questions whether the reported significance is supported after considering that many values are below 1.0 μg/mL, potential confounding from outliers, lack of clear stage I vs stage II differences, and wide scatter across EOC groups.\"}]","Is C3c structure useful as biomarkers for epithelial ovarian cancer? - Editorial | PDF",1790664766]